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Purpose: Changes in the expression of water channels or aquaporins (AQP) have been reported in several diseases.
However, such changes and mechanisms remain to be evaluated for retinal injury. This study was designed to analyze
changes in the expression of AQP4 following elevation of intraocular pressure (IOP) and after intravitreal endothelin-1
injection and the potential involvement of the ubiquitin-dependent proteasome.
Methods: Retinal injuries were induced by the elevation of intraocular pressure in rat eyes using the Morrison model or
following endothelin-1 intravitreal injection. Immunohistochemistry using a combination of glial fibrillary acidic protein
(GFAP) and aquaporin-4 antibodies were employed to follow changes in the optic nerve head astrocytes. Real-time
quantitative PCR (Q-PCR) was used for measuring changes in AQP4, ubiquitin hydrolase L1 (UCH-L1), and β-actin
messages. Changes in AQP4, caspase-3, thy-1, ubiquitination, and GFAP expression were also followed in total retinal
extracts using western blotting. An S5a column was used to purify ubiquitinated proteins.
Results: In retinas of both injury models, there was an upregulation of GFAP (a marker of astrogliosis), caspase-3, and
downregulation of thy-1, a marker for retinal ganglion cell stress, and decreased retinal AQP4 mRNA and protein levels
as determined by Q-PCR, and western blotting, respectively. By contrast, IOP enhanced expression and co-localization
of GFAP and AQP4 in optic nerve astrocytes. AQP4 was detected in affinity-purified ubiquitinated proteins using S5a
column, suggesting that AQP4 is a target for degradation by the ubiquitin-dependent proteasome. While elevation of IOP
induced an increase in ubiquitination in retinal extracts, it decreased ubiquitination in optic nerve extracts as detected by
western blotting. Enhanced ubiquitination and decreased ubiquitination appear to correlate with AQP4 expression. IOP
decreased UCH-L1 (or protein gene protein [PGP9.5]) in retinal extracts as judged by Q-PCR.
Conclusions: The enhanced expression of AQP4 in optic nerve astrocytes following elevation of IOP may explain the
astrocytic hypertrophy normally seen in glaucoma patients and may involve alteration in the activity of ubiquitin-
dependent proteasomal degradation system. The decreased ubiquitination in the optic nerve may lead to increased levels
of proapoptotic proteins known to be degraded by the proteasome, and thus to axonal degeneration in glaucoma.
The  glaucomas  represent  a  heterogeneous  group  of
diseases  that  result  in  a  progressive  optic  neuropathy
characterized  by  functional  and  structural  impairment  of
ocular  tissues.  Particularly  affected  are  the  trabecular
meshwork, the optic nerve head, and retinal ganglion cells.
One of the risk factors in primary open angle glaucoma
(POAG) is an associated elevation in intraocular pressure
(IOP) [1]. Elevation of IOP results in blockade of axonal
transport in animals as well as displacement of the optic nerve
head [2–7]. In addition, high levels of endothelin-1 (ET-1)
have been observed in patients with normal tension glaucoma,
open angle glaucoma, and animal models of glaucoma [8–
11].  Low  doses  of  ET  administered  intravitreally  have
produced similar ocular nerve damage, optic nerve cupping,
and inhibition of anterograde axonal transport in the optic
nerve  [12–15].  Abnormalities  in  water  balance  play  an
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important  role  in  the  pathophysiology  of  a  variety  of
neurologic  disorders.  Neuronal  activity  is  associated  with
redistribution of water. While shrinkage of the extracellular
space  around  active  synapses  is  observed,  enlarged
extracellular space volume at distal sites also occurs [16].
The  discovery  of  aquaporins  (AQPs)  has  provided  a
molecular basis for understanding water transport in several
tissues, including the ocular system [17]. At least six AQPs
are expressed in the eye: AQP0 major intrinsic protein (MIP)
in lens fiber; AQP1 in cornea endothelium, ciliary and lens
epithelia,  trabecular  meshwork,  and  retinal  photoreceptor
cells; AQP3 in conjunctiva; AQP4 in ciliary epithelium and
retinal  Muller  cells;  AQP5  in  corneal  and  lacrimal  gland
epithelia [18]; and AQP9 in retinal ganglion cells [19].
Hypoxia, ischemia, hyperosmotic stress, and elevated ET
levels are associated with changes in the densities of AQP
expression. Interestingly, such insults are key risk factors in
the development of glaucomatous optic nerve neuropathy.
However, the expression of ocular aquaporins upon retinal
injuries  has  not  been  fully  characterized.  In  addition,  the
hallmark of glaucoma is the demyelination and degeneration
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2of the optic nerve and death of retinal ganglion cells, leading
eventually to irreversible blindness. Axonal degeneration in
many  neurodegenerative  diseases  (e.g.,  Alzheimer  and
Parkinson diseases) appears to be mediated via abnormalities
in  the  activities  of  the  ubiquitin-proteasomal-degradation
system (UPS). Elevated IOP has been found to block both
anterograde and retrograde axonal transport in the optic nerve
head  in  animals  [2–7]  which,  in  turn,  may  impede  the
anterograde transport of ubiquitin in the optic nerve axons
[20],  and  thus  impair  the  proteasomal  function  known  to
control the levels of several pro-apoptotic proteins [21]. In
addition,  ubiquitin  hydrolase  L1  (UCH-L1)  activity  and
expression  has  been  shown  to  correlate  with  axonal
degeneration.  Using  two  models  of  retinal  injuries:  1)
intravitreal  injection  of  ET-1;  and  2)  elevation  of  IOP
according to the Morrison procedure, changes in AQP4 and
ubiquitination levels were evaluated in retinal and optic nerve
extracts.
METHODS
Materials:  Anti  procaspase-3  antibodies  were  from  Cell
Signaling  (Boston,  MA)  and  monoclonal  anti-thy-1
antibodies  were  from  Chemicon,  (Temecula,  CA).  AQP4
(mouse and rabbit) and thy-1 rabbit antibodies were from
Santa Cruz Inc (Santa Cruz, CA) and monoclonal anti-glial
fibrillary acidic protein antibodies were from Neomarkers
(Fremont,  CA).  Monoclonal  anti-tubulin  antibodies  were
from Upstate Inc (Lake Placid, NY), and secondary antibodies
(donkey anti-mouse conjugated Alexa 633, goat anti-rabbit
conjugated Alexa 633, and goat anti-mouse conjugated Alexa
488) were from Invitrogen Inc (Carlsbad, CA).
Intravitreous  injection  of  ET-1:  HEPES-buffered  ET-1  or
HEPES vehicle buffer alone were injected intravitreally as
described [15]. Male Brown Norway retired breeder rats were
anesthetized and 4 µl of HEPES-buffered ET-1 (2 nmol) or
HEPES vehicle, was injected into the vitreous of the left eye
with a 30-gauge needle attached to a syringe (µl 710, 22s
gauge;  Hamilton  Co.,  Reno,  NV)  by  polyethylene  tubing
(PE-20, Clay Adams Brand; BD Biosciences, Sparks, MD).
Rats were anesthetized with intramuscular cocktail (xylazine/
ketamine/acepromazine). Anesthesia cocktail for sedation (9
ml) was prepared as follows: 5 ml ketamine (stock 100 mg/
ml) + 0.5 ml xylazine (stock 100 mg/ml) + 1 ml acepromazine
(stock 10 mg/ml) + 2.5 ml sterile water. The animal is given
1 ml/kg weight. During intravitreous injections, retinas were
observed through the pupil with a surgical microscope (model
Stiffuss S; Carl Zeiss, Thornwood, NY). During introduction
of solution into the vitreous, a transient blanching of the retina
was observed in all animals. One minute after injection, all
retinas appeared normal in color. All studies were conducted
in accordance with National Institutes of Health guidelines,
the ARVO Statement for the Use of Animals in Ophthalmic
and  Vision  Research,  and  guidelines  of  the  University  of
Texas Health Science Center Committee on Animal Welfare.
After  48 h, 72 h, or  7  days  post ET-1  injection,  all  rats
were   euthanised  by  an   i.p.  injection  of  pentobarbital
−1 100 mg kg  ), eyes  were dissected and processed for western
blotting as described in 2.5 or for Q-PCR as described in 2.6.
The Morrison glaucoma model: Male Brown Norway retired
breeder rats weighing 200-300 g were used and fed standard
chow.  Prior  to  experimentation,  the  animals  were  housed
individually  in  rat  gang  cages  in  an  environmentally
controlled room and maintained on a 12 h:12 h light-dark
cycle and allowed tap water ad libitum. IOP was elevated in
one eye, by following the description by Morrison et al. [22]
in which 50 μl of 1.8 M saline was injected into the episcleral
veins of one eye of anesthetized rats such that blanching was
observed. This procedure produces scarring of the trabecular
meshwork (TM) with a resultant rise in IOP and damage to
the  optic  nerve  [23].  Rats  were  housed  post-surgically  in
constant low light (<90 lux) to minimize effects of circadian
influences  on  IOP.  After  the  rats  were  stabilized  and
conscious, IOP measurements were taken with a Tonolab
rebound  tonometer  (Colonial  Medical  Supply  Co.  Inc.,
Franconia, NH) after 0.1% proparacaine, a topical anesthesia,
was applied. Animals were weighed periodically. IOP was
initially monitored twice a week for up to 10–14 days and
subsequently monitored on a weekly basis, once the IOP was
greater than 25% of baseline IOP values. IOP values at each
time were recorded as an average of nine consecutive Tonolab
measurements  for  each  eye.  Mean  intraocular  pressure
changes over the time of pressure elevation were calculated
for each eye. IOP exposure is the cumulative IOP difference
between  the  hypertensive  (treated)  eye  to  control
(normotensive) eye and was calculated for each animal as
mmHg  days  as  previously  described  by  McKinnon  et  al.
[24]. Accordingly, IOP exposure for each rat was calculated
by performing separate area-under curve (AUC) integration
of IOP over the days of exposure for the treated and control
eye. The integral value of the control eye was subtracted from
that of the experimental treated eye to yield the “IOP-integral
difference”  and  was  expressed  as  mmHg  days.  Rats  with
elevated IOP were maintained for 500–700 mmHg days post-
surgery. Comparisons between groups of various mmHg days
of IOP elevation were made using one-way ANOVA and
multiple comparison tests at p <0.05. Rats (n=3) were also
injected with isotonic saline (sham) into one eye and kept
under the same conditions as those that received hypertonic
saline for 140 days. Rat eyes were dissected, and either fixed
in  formalin  for  immunohistochemistry  or  processed  for
western blotting or Q-PCR. The contralateral eye served as
the control.
Double immunofluorescence labeling studies: Rat eyes were
dissected, fixed in formalin, embedded in paraffin, and 5 µm
sections were obtained using a microtome. Retina sections
were  deparaffinized  in  xylene,  rehydrated  using  ethanol
washes,  and  washed  with  PBS  (150  mM  NaCl,  3.8  mM
NaH2PO4, 16.2 mM Na2HPO4, Sigma-Aldrich Co. St. Louis,
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PBS washes before nonspecific binding was blocked by 5%
BSA in PBS. The sections were incubated for 2 h at room
temperature  with  a  proper  mixture  of  primary  antibodies:
1:400 thy-1, 1:100 AQP4, and 1:100 GFAP. Coverslips were
rinsed with PBS three times and allowed to incubate for 1 h
in  the  dark  at  room  temperature  in  a  mixture  of  proper
secondary antibodies: donkey antimouse conjugated Alexa
633, goat antirabbit conjugated Alexa 633, and 1:400 goat
antimouse conjugated Alexa 488. This was followed by three
washes in 1X PBS and one final wash in deionized water.
Coverslips were mounted on glass slides in antifade medium
(FluorSave; Calbiochem, La Jolla, CA) and allowed to dry for
20 min in the dark. Retinal and optic nerve sections were
viewed and images were taken with Zeiss LSM 410 confocal
microscope.  Control  was  performed  by  omitting  primary
antibodies.
Western blotting: Western blotting was performed on either
total  retinal  lysates  or  enriched  plasma  membrane  and
cytosolic  fractions.  Total  retinal  lysate  was  prepared  by
dissecting  retinas  from  eyes  and  solubilized  them  into  a
250 μl of a solution containing 20 mM Tris (pH 7.4), 10%
sucrose, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 1% Triton
X-100, 0.1% sodium dodecyl sulfate, and protease inhibitors
at 4 °C. Retinal lysates were incubated for 30 min on ice then
briefly  sonicated  before  centrifugation  at  14,000x  g  for
15  min.  The  supernatant  was  collected  and  protein
concentration  was  measured  using  a  bicinchoninic  acid
(BCA) protein assay kit (Sigma, St. Louis, MO) with BSA as
the standard. Plasma membrane fractions were enriched by
dissecting retinas from eyes and homogenized them 4 °C ,
using a Potter homogenizer (60 strokes), into 700 μl of a
solution  containing  20  mM  Tris  (pH  7.4),  10%  sucrose,
2  mM  EDTA,  2  mM  EGTA,  50  mM  NaF,  and  protease
inhibitors. This was followed by centrifugation at 3,000x g for
5  min.  The  unbroken  tissue  was  sonicated  7  times  then
centrifugation was repeated. The retinal supernatant was then
centrifuged for 30 min at 100,000x g at 4 °C. The resultant
supernatant (enriched cytosol) and pellet (enriched plasma
membrane) were collected for protein measurement using the
BCA protein assay. Optic nerves, 1.5 cm in length, were
removed and homogenized in 100 μl of BUST sample buffer:
2% β-mercaptoethanol, 5 M urea, 1% SDS, 0.1 M Tris, and
0.02% bromophenol blue, pH 7.4. Proteins were separated by
10% sodium dodecyl sulfate-PAGE, with 20–30 μg (enriched
fraction) or 100 μg (total retinal extract) of protein loaded in
each  lane.  Gels  were  equilibrated  for  10  min  at  room
temperature  in  a  transfer  buffer:  192  mM  glycine,  20%
methanol and 25 mM Tris-HCl, pH 8.3. Afterwards, gels were
electroblotted  on  nitrocellulose  membranes  for  75  min  at
100 V using a Bio-Rad electroblotting unit. The membranes
were  dried  at  room  temperature.  Western  blotting  was
performed using Amersham Chemiluminescent Kit (Bedford,
MA).  Membranes  were  incubated  with  1  μg/ml  primary
antibodies for 60 min and with 1:10,000 secondary antibody
for 30 min . Next, membranes were exposed to an X-ray film
for 30 s, 1 min, and 3–5 min, and then the film was later
developed. Afterwards, membranes were stripped and probed
with anti-α-tubulin antibodies for normalization. Experiments
were repeated three times. Band densities were quantified
with image-analysis software (Scion, Frederick, MD), and the
intensity  of  AQP4/thy-1/GFAP/caspase-3  bands  was
normalized for every sample relative to the intensity of the
respective tubulin bands.
Real-time analyses of AQP4/UCH-L1/β-actin mRNA levels:
Retinas  were  dissected  from  eyes,  and  total  RNA  was
extracted with Trizol (Life Technology, Carlsbad, CA) by
following the manufacturer’s instructions. In this study, 5 μg
of total RNA was reverse transcribed using the iscript kit (Bio-
Rad, Herculez, CA) according to manufacturer’s instructions.
Control Q-PCR reactions were performed in the absence of
cDNA templates. β-actin was used as a housekeeping gene.
TABLE 1. QUANTITATIVE PCR PRIMER SEQUENCES AND EXPECTED PRODUCT SIZES.
Primer name Forward primer (5’- 3’) Reverse primer (5’-3’) Product size (bp)
AQP4 CGGTTCATGGAAACCTCACT CATGCTGGCTCCGGTATAAT 191
UCH-L1 CTAGGGCTGGAGGAGGAGAT CCCAATGGTACCACAGGAGT 189
β-actin TGTGATGGTGGGAATGGGTCAG TTTGATGTCACGCACGATTTCC 514
Quantification of relative RNA concentrations was achieved by using the comparative CT method  using β-actin gene as reference.
TABLE 2. PRIMER OPTIMIZATION.
Primer name Denaturation Annealing Extension Number of cycles
AQP4 95°C 30 s 60
oC 30 s 72
oC 60 s 45
UCH-L1 95
oC 30 s 60
oC 30 s 72
oC 60 s 40
β-actin 95
oC 60 s 60
oC 60 s 72
oC 120 s 40
All primers were optimized for annealing temperatures and cycles.
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optimization described in Table 2. The melting curves were
generated to detect the melting temperatures of the specific
products immediately after the PCR run. The relative mRNA
levels were determined by the comparative CT (cycle number
at threshold) method as described in PE Biosystems User
Bulletin #2. The fold change was determined by the following
formula:
Change = 2 − Δ(ΔCt),
where ΔCt = Cttarget − Ctβ-actin,  and  “target”  is  the gene of
interest. The first delta is the difference between the ΔCt
values of the treated eye and the control eye (ΔΔCt) and
represents the corrected shift of the analyzed gene.
To verify sequence of products, we performed regular
PCR and ran the PCR products on a 1.5% agarose gel in
parallel  with  100  bp  DNA  markers  before  staining  with
ethidium bromide. Bands were cut and sequenced to verify
identity. The authenticity of PCR products was confirmed
using  a  BLAST  search  of  the  sequence  through  National
Center for Biotechnology Information.
Statistical analyses of data: Data are reported as means±SEM.
All experiments were repeated at least three times with up to
three to four replicates per condition each time. Statistical
significance was determined by using one-ANOVA and the
Tukey multiple comparison tests at p<0.05.
RESULTS
As shown in Figure 1, IOP significantly increased in eyes with
episcleral vein injection of hypertonic saline compared to the
contralateral eyes and was maintained for up to 140 days post-
surgery.  The  experimental  glaucomatous  eyes  showed  a
significant  and  sustained  increase  in  the  IOP  during  the
Figure 1. Introcular pressure measurements in a Morrison rat model
of glaucoma. Hypertonic saline was given in one eye of each Brown
Norway rat to elevate intraocular pressure (IOP) and the contralateral
eye was allowed to serve as a control. Each data point represents the
average of nine consecutive IOP measurements (mean±SEM) for
each eye in mmHg IOP values.
experimental period. Two days before surgery, the average
baseline  IOP  for  both  control  and  treated  eyes  was
21±0.5 mmHg. However, the average IOP in the treated eye
increased  and  peaked  (days  varies  between  animals)  at
27±0.7  mmHg.  Fortune  et  al.  [25]  reported  an  estimated
6 mmHg difference between control and elevated IOP eyes
following similar surgery. While IOP readings in the current
study were obtained using the Tonolab, earlier studies have
reported higher IOP readings of up to 35–50 mmHg using the
Tonopen XL. Moore et al. [26] have reported that the Tonopen
XL significantly overestimates IOP in animals, and Pease et
al. [27] suggested that the Tonolab is superior to Tonopen XL
in measurement of IOP in rat and mouse eyes.
Figure  2.  A  single  intravitreous  ET-1  injection  and  elevated
intraocular  pressure  reduced  AQP4  mRNA  in  rat  retinas.  Four
microliters of HEPES-buffered ET-1 (2 nmol) or HEPES vehicle,
was injected into the vitreous of the left eye and 2 days later, retinas
were removed, total RNA was isolated and transcribed into cDNA.
IOP was elevated using the Morrison Method [22]. mRNAs for
AQP4  transcripts  were  significantly  lower  compared  to  controls
following 2 days of ET-injection (~ 45%, A). Elevation of IOP also
decreased AQP4 transcripts by ~ 33%, as determined by quantitative
real-time PCR (B). Gene expression data of AQP4 is calculated after
normalizing with β-actin. Data are expressed as ratio of control±SEM
and  the  asterisk  denotes  a  significant  difference  compared  with
control-retinas at p<0.05.
Molecular Vision 2008; 14:1770-1783 <http://www.molvis.org/molvis/v14/a209> © 2008 Molecular Vision
1773Similar  observations  have  been  cited  with  human
glaucoma patients. For example, Weisberg et al. [28], Skaf et
al. [29], and Haus et al. [30] reported higher IOP readings
when using the Tonopen XL in glaucoma patients compared
to readings obtained using the rebound tonometer ICT and
other  instruments,  and  suggested  that  measurements  are
probably  falsely  elevated  when  using  the  Tonopen  XL.
Isotonic saline-injected (sham) rats, maintained for up to 140
days  post-injection,  showed  no  increase  in  IOP.  AUC
measurements, yielding the IOP-integral difference of IOP
elevation over days of exposure for treated eye and control
eye, were calculated for each rat and represented as mmHg
days. Experimentally IOP-elevated Brown Norway rats with
IOP corresponding to 610±102 mmHg days were analyzed in
the study.
Effect of intravitreal injection of ET-1 and elevated IOP
on AQP4 in rat retinas: Several studies have shown that ET-1-
injection induced hypoxia to the optic nerve, astrogliosis and
axonal  loss  [8–15].  Therefore,  the  effect  of  intravitreal
injection of ET-1 on AQP4 expression in retina was tested. As
shown in Figure 2A, ET-1 injection resulted in a decrease in
AQP4 mRNA as determined by Q-PCR. Five out of 7 rats
(71%) showed a significant reduction in mRNA (54±11%,
p<0.001 versus HEPES-injected or control, Figure 2A), and
there was a similar reduction in AQP4 mRNA upon elevation
of IOP in six out nine rats (67%, 62±12, p=0.001, Figure 2B).
A similar reduction was observed in AQP4 protein levels in
ET-1 injected and IOP-elevated eyes. As shown in Figure 3A,
nine out of 11 rats (82%, Figure 3A) showed a decrease in
AQP4 protein levels in ET-1 injected eyes (70±10%, p<0.05)
and AQP4 protein levels decreased in five out seven rats
following elevation of IOP (71%; 72±12% p<0.001, 3C).
ET-1  injection  also  resulted  in  an  increase  in  GFAP
(Figure 4A, 380±100%, p<0.005) and similarly, elevation of
IOP  increased  GFAP  expression  in  all  screened  rats
(133±10%,  p<0.005,  Figure  4B,C,  n=6).  Caspase-3
upregulation  is  involved  in  initiating  apoptosis  and  not
surprisingly was induced in both injury models. ET-injection
increased  procaspase-3  protein  levels  (300±80%,  p<0.05,
Figure 5A, n=6) and high IOP also increased procaspase-3
levels (180±40%, p<0.05, Figure 5B, n=6). By contrast, in
both models, there was a reduction in thy-1 protein levels, a
marker  for  RGC  stress  (Figure  6A,B,  respectively,  n=6;
75±10%, p<0.05 in both models).
Immunohistochemical analyses of AQP4 in Morrison rat
model of glaucoma: The rat optic nerve head (ONH) possesses
Figure 3. Intravitreal ET-1 injection and
elevated  intraocular  pressure  reduced
AQP4  protein  levels  in  rat  retinas.
Following  retinal  injuries  with  ET-
injection  or  elevation  of  IOP,  retinas
were dissected and plasma membrane
proteins  were  isolated.  Thirty
microgram protein was loaded into each
lane.  A:  Immunoreactive  bands  for
AQP4  and  α-tubulin  2  days  after
intravitreal injection of ET-1 showing a
significant reduction in AQP4 protein
levels. Also, quantitative measurement
using  western  blot  showed  that
elevation  of  IOP  decreased  AQP4
protein  levels  by  ~  30%  (C).
Densitometric quantification is shown
in B and D. Data are expressed as a ratio
of the control value and each column
represents  mean±SEM.  The  asterisk
denotes statistical significance of AQP4
in  ET-injected  retinas  versus  control
(p<0.05) and the double asterisk denotes
statistical  significance  of  AQP4  in
elevated  IOP-retinas  versus  control
(p<0.001)  as  determined  by  one-way
ANOVA  and  Tukey  multiple
comparison test. Abbreviations: control
eye  (C),  ET-injected  eye  (E),  and
elevated IOP (T).
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regions [31]: the neck region, located at the level of the sclera;
the transition region, an extension zone below the neck region;
and the posterior region, which is characterized by myelinated
axons.  Astrogliosis  characterized  by  increased  labeling  of
GFAP and altered extracellular matrix proteins expression is
observed in glaucomatous ONH [32,33]. However, it is not
presently known if AQP4 expression is augmented in ONH
astrocytes  exposed  to  IOP  elevation  that  results  in
hypertrophy.
Whereas AQP4 levels appeared to decrease in the retina,
based on immunohistochemistry results, it was possible to
detect  qualitative  changes  in  immunoreactive  AQP4,  and
GFAP levels in the optic nerve of rats with elevated IOP. In
the control group, immunostaining for AQP4 was visible in
the  three  regions  of  the  ONH  (Figure  7).  The  pattern  of
distribution of AQP4 was similar to the pattern of GFAP-
positive cells, suggesting that expression of AQP4 was located
in astrocytes. In the group with chronic elevated IOP, AQP4
expression was also seen in the three regions of the ONH. A
greater number of stained cells were visible as compared with
those of the control group (Figure 7). Immunohistochemical
studies on retinal sections of ET-1 intravitreally injected rats
did  not  show  significant  changes  in  AQP4  compared  to
HEPES-injected eyes (data not shown).
The difference between retina and optic nerve AQP4 data
could  be  explained  due  to  differences  in  activities  of  the
ubiquitin-dependent proteasome. Several channels have been
shown to undergo ubiquitination and degradation. Affinity
purified ubiquitinated proteins on an S5a column from rat
retinas revealed the presence of 87 and 100 kDa AQP4 high-
molecular weight isoforms, suggesting that AQP4 is a target
for  degradation  by  the  ubiquitin-dependent  proteasome
(Figure 8). Levels of ubiquitination in both retinal and optic
nerve protein extracts were analyzed by western blotting using
monoclonal  anti-ubiquitin  antibodies.  Although
Figure 4. Glial fibrillary acidic protein
(GFAP)  protein  is  upregulated
following  intravitreal  ET-1  injection
and  elevation  of  intraocular  pressure.
Following  retinal  injuries  with  ET
injection  or  elevation  of  IOP,  retinas
were  dissected  and  cytosolic  proteins
were isolated. Fifty microgram protein
was  loaded  into  each  lane.  GFAP,  a
cellular marker for retinal injury, was
upregulated in both injury models but
with significant induction following ET
injection  (380+100%)  compared  to
elevation  of  IOP  (133+10%).
Densitometric quantification is shown
in C and D. Data are expressed as a ratio
of the control value and each column
represents  mean±SEM.  The  asterisk
denotes statistical significance of GFAP
in  ET-injected  retinas  versus  control
(p<0.005)  and  the  double  asterisk
denotes statistical significance of GFAP
in elevated IOP-retinas versus control
(p<0.005), as determined by one-way
ANOVA  and  Tukey  multiple
comparison test. Abbreviations: control
eye  (C),  ET-injected  eye  (E),  and
elevated IOP (T).
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lysine  residues,  ubiquitination  activity  can  extend  the
ubiquitin  chains  by  the  sequential  addition  of  multiple
ubiquitin  moieties.  This  is  why  when  the  anti-ubiquitin
antibodies are used, immunoreactive smear is detected that
reflects the covalent attachment of multiple ubiquitin chains
to  individual  protein  molecule.  Western  blot  with  anti-
ubiquitin  antibodies  revealed  a  characteristic  ubiquitin-
positive smear in each lane corresponding to the amount of
ubiquitination on proteins, and elevation of IOP enhanced
ubiquitination  in  retinal  extracts  while  decreased
ubiquitination  in  optic  nerve  extracts  (Figures  9A,B,
respectively,  n=10).  Enhanced  ubiquitination  may  reflect
accelerated degradation of proteins, including AQP4, which
may explain the different effects of elevated IOP on AQP4
levels in retina versus optic nerve. Elevated IOP attenuated
expression of UCH-L1 in retina as judged by Q-PCR (8 out
10  rats,  68±8%,  p<0.005,  Figure  10).  Although  the
downregulation  of  ubiquitin  hydrolase  may  explain  the
enhanced ubiquitination in retina, UCH-L1 protein levels did
not change significantly in retinas with elevated IOP (data not
shown). Overall, in both retinal injury models, both AQP4 and
thy-1 levels were decreased in retinas. By contrast, AQP4
increased in ONH astrocytes, a mechanism that may involve
alterations of the ubiquitin-dependent proteasomal activities.
Also, both procaspase-3 and GFAP levels were increased
following retinal injuries.
DISCUSSION
The role of AQP4 in glaucoma has not been fully understood.
In the current study, elevation of IOP appears to affect AQP4
levels  differently  in  the  retina  and  ONH.  While  AQP4
decreased in retina, it increased in the ONH and colocalized
with GFAP. These observations suggest that IOP elevation is
an important factor for increasing the levels of AQP4 and
GFAP, which could promote glial activation at the optic nerve.
The upregulation of water channels in rat ONH with elevated
IOP could lead to hypertrophy. Patients with normal tension
glaucoma [34] as well as POAG [35] have a larger optic disc
Figure  5.  Procaspase-3  protein  is
upregulated following intravitreal ET-1
injection  and  elevation  of  intraocular
pressure.  Procaspase-3  (31  kDa)  is
normally cleaved to a 17 kDa fragment
that is fully active. However, in both
models,  an  upregulation  of  the
procaspase-3  form  was  observed
without  detection  of  the  17  KDa
fragment. A: Immunoreactive bands for
procaspase-3 and α-tubulin 2 days after
intravitreal injection of ET-1 showing a
significant  increase  in  procaspase-3
protein levels (300%). B: Quantitative
measurement  using  western  blot  also
showed that elevation of IOP increased
procaspase-3 protein levels by ~ 180%.
Isolated cytosolic proteins (50 μg) were
loaded  into  each  lane.  Densitometric
quantification is shown in figures C and
D. Data are expressed as a ratio of the
control  value  and  each  column
represents  mean±SEM.  The  asterisk
denotes  statistical  significance  of
procaspase-3  in  ET-injected  retinas
versus control (p<0.05) and the double
asterisk denotes statistical significance
of procaspase-3 in elevated IOP-retinas
versus control (p<0.05), as determined
by  one-way  ANOVA  and  Tukey
multiple  comparison  test.
Abbreviations:  control  eye  (C),  ET-
injected eye (E), and elevated IOP (T).
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1776compared to normal patients. Whether the upregulation of
AQP4 explains astrocyte hypertrophy in the ONH is not clear
and may require a selective AQP4 knockout in ON astrocytes.
The lack of selective AQP4 inhibitors also hampers a quicker
evaluation  of  whether  AQP4  inhibition  will  prevent
hypertrophy upon elevation of IOP. More importantly, a new
role for astrocytic AQP4 in the development of neuromyelitis
optica (NMO) has been reported. NMO is an autoimmune
disease characterized by severe optic neuritis and transverse
myelitis where serum from patients is enriched with anti-
AQP4  antibodies  leading  to  loss  of  AQP4  in  the  active
perivascular NMO lesions. GFAP was strongly stained at the
reactive astrogliosis surrounding the lesions and therefore, it
has been suggested that astrocytic impairment is associated
with humoral immunity against AQP4 [36].
In addition, AQP4 deletion in mice is neuroprotective in
a transient ischemia model of retinal injury [37] and hypoxia
induced  a  marked  decrease  in  AQP4  mRNA  levels  in
astrocytes in vitro [38], suggesting that the reduction of AQP4
levels may be a beneficial mechanism. However, AQP4 also
appears  to  play  an  important  role in ion homeostasis and
+  “Kspatial  buffering”  [39–43]. Retinal water transport  or
changes  in  extracellular  space  volume  appear  to  parallel
transglial  K+  currents,  and  mice  lacking  AQP4  have  a
significant  delayed  cellular  reuptake  of  K+  from  the
extracellular space (ECS) [44–46]. K+ spatial buffering within
the inner retina occurs via the redistribution (siphoning) of
excess  K+  from  the  extraneuronal  space  toward  fluid
reservoirs  of  low  K+  (or  sinks),  such  as  vitreous  body,
subretinal space and blood vessels [47,48]. This is especially
important since firing of neurons changes the extracellular
concentration of K+ ions ([K+]o) due to excess K+ ions liberated
from neurons into the intracellular space and causes a slow
depolarization of glial cells which have the ability to maintain
[K+]o  at  a  constant  level.  Spatial  K+  buffering  generates
osmotic  gradients  leading  to  uptake  of  sodium  and
Figure 6. A single intravitreous ET-1
injection  and  elevation  of  intraocular
pressure decreased thy-1 protein levels
in rat retinas. Thy-1 expressed by retinal
ganglion cells is widely used as marker
for RGC early stress and was shown to
be reduced following ET injection and
elevation of IOP by ~ 25%. Data are
expressed as a ratio of the control value
and  each  column  represents  mean
±SEM. Densitometric quantification is
shown in C and D. The asterisk denotes
statistical significance of thy-1 in ET-
injected retinas versus control (p<0.05)
and  the  double  asterisk  denotes
statistical  significance  of  thy-1  in
elevated  IOP-retinas  versus  control
(p<0.05)  as  determined  by  one-way
ANOVA  and  Tukey  multiple
comparison test. Abbreviations: control
eye  (C),  ET-injected  eye  (E),  and
elevated IOP (T).
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1777bicarbonate that causes the intracellular osmolarity to increase
and  drives  water  into  the  glial  cells  through  AQP4.  An
imbalanced reduction of AQP4 levels may therefore impair
retinal K+ buffering and uncontrolled increases in [K+]o may
induce  uncontrolled  hyperexcitability  and  abnormal
synchronization of retinal neurons.
In  addition,  the  expression  of  several  aquaporins
including AQP1, AQP2, AQP3, and AQP5 decrease with
aging  [49–51],  and  therefore  AQP4  expression  may  also
decrease with aging. Interestingly, human retinal glial cells
display an age-dependent decline in their K+ conductance (an
estimated 50% reduction), in cells from donors aged 60 years
and more [52], and it remains to verify if such attenuation is
linked to or parallels changes in AQP4 retinal levels.
The  difference  in  affecting  AQP4  protein  levels  may
involve  the  ubiquitin-dependent  proteasome.  Western  blot
analysis detected high molecular weight isoforms of AQP4
and these appeared to be ubiquitinated isoforms. S5a-affinity
purified  ubiquitinated  proteins  were  enriched  in  high
molecular weight AQP4 isoforms. Increased IOP appeared to
enhance ubiquitination in the retina but decreased it in the
optic nerve. Elevated IOP decreased UCH-L1 mRNA levels
in  the  retina,  and  this  may  also  explain  the  increased
ubiquitination in retina. Although such an observation may
explain the different changes in AQP4 between the retina and
optic nerve, other mechanisms cannot be ruled out. Bizzi et
al. have shown that ubiquitin utilizes anterograde transport in
the optic nerve axons exclusively with the slow component b
(SCb), known to carry cytoskeletal and cytoplasmic proteins
[21]. It is well documented that elevated IOP blocks both
anterograde and retrograde axonal transport in the ONH in
animals [2–7]. Therefore it is possible that the elevation of
Figure 7. Expression of immunoreactive AQP4 (green) and glial fibrillary acidic protein (GFAP; red) in the optic nerve of rats exposed to
experimentally elevated intraocular pressure. Elevation of IOP was performed as described by Morrison et al [22]. The contralateral (control)
eyes showed modest AQP4 and GFAP expression (B-D). In contrast, AQP4 and GFAP labeling at the optic nerve was consistently more
intense in eyes exposed to elevated IOP compared to control eyes (F-H). A representative figure of the optic nerve is shown for one rat exposed
to >500 mmHg days of IOP elevation. A and E are DIC images, B and F represent AQP4 labeling, C and G represent GFAP labeling, and
D and H represent merged images of AQP4 and GFAP labeling (yellow). Scale bars represents 50 μm. Staining was performed without primary
antibodies (I-L) that shows no labeling and was used as a negative control.
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1778IOP  would  inhibit  ubiquitin  transport  to  axons  and  thus
explain the attenuated ubiquitination in axons, whereas the
accumulation  of  ubiquitin  in  retina  could  account  for  the
enhanced ubiquitination and the downregulation of AQP4
protein. More important, the attenuation of ubiquitination in
axons may result in accumulation of several proapoptotic
proteins (e.g., caspases, Bax and Bad) known to be degraded
by  the  proteasome  [20]  and  thus  contributes  to  axonal
degeneration in glaucoma.
There  are  several  studies  that  looked  at  similarities
between glaucoma and other neurodegenerative diseases and
our data found a common link. UCH-L1 has been implicated
in many neurodegenerative diseases, such as gracile axonal
dystrophy  in  mice,  familial  Parkinson  disease  [53–55],
diabetic  spiral  ganglion  cells  in  WBN/Kob  rats  [56],  and
lepromatous  eyes  [57].  The  current  finding  that  UCH-L1
mRNA levels are decreased with elevated IOP (Figure 10) is
consistent  with  the  findings  in  other  neurodegenerative
diseases. However, the involvement of other components of
the proteasomal system may contribute as well but needs
further investigation.
By western blot, we demonstrated an increase in GFAP
protein levels using two different models of retina injury:
intravitreal  ET-1  injection  and  the  Morrison  model  of
glaucoma. Increased GFAP labeling was similarly observed
at the rat ONH exposed to elevated IOP as described by
Johnson et al. [58] and Prasanna et al. [59]. It is well known
that a universal early cellular marker for retinal injury is the
upregulation  of  the  intermediate  filament  protein,  GFAP.
Although  the  exact  function  of  GFAP  is  not  known,  its
immunoreactivity is commonly used as an index of gliosis/
hypertrophy  [32,33].  In  POAG  patients,  increased  GFAP
Figure 8. Detection of aquaporin-4 (AQP4) in isolated ubiquitinated
protein fractions. S5a is a protein subunit of the proteasome that binds
ubiquitinated  proteins  and  can  be  used  to  purify  ubiquitinated
proteins. Retinal ubiquitinated proteins were purified on an S5a
affinity column (Biomol Inc) before they were eluted with SDS-
sample  buffer.  Next,  they  were  separated  on  SDS-PAGE  then
subjected to western blotting using anti-AQP4 antibodies. As shown
in this figure, higher molecular weight forms of AQP4 were detected
(87 and 100 kDa proteins). Lanes 1-3 are three different retinal
preparations from different rats.
staining was observed in astrocytes at the ONH that correlated
strongly with the severity of glaucoma [32,33]. Tanihara et al.
[60]  have  shown  that  elevation  of  IOP  in  primates  was
accompanied by increased GFAP mRNA and Yu et al. [61]
observed elevation of IOP increased GFAP protein levels
without significant changes in GFAP mRNA levels. Ju et al.
[62]  demonstrated  that  chronic  ocular  hypertension  was
accompanied  by  increased  GFAP  expression  in  rats.
Furthermore,  Lau  et  al.  have  shown  that  intravitreal  ET
injection increased GFAP expression in rat retina [63]. Thus
increased GFAP expression appears to accompany damage to
the optic nerve and retina.
The present data are also in agreement with earlier studies
that reported elevated IOP induced activation of caspase-3
[24,64–66].  Other  groups  have  used  axotomy  and  shown
activation of caspases [67–69]. In the present study, western
blot of caspase-3 detected the 31 kDa pro-caspase-3 form and
not the active cleaved caspase-3 (17 kDa), although it has been
suggested the antibody can recognize both species. The reason
for that could be due to many factors. Johnson et al. [70] used
the same antibody and detected only the procaspase-3 and not
the cleaved fragment, and Garcia-Domingo et al. [71] used
antibodies  against  caspase-3  and  were  able  to  detect
procaspase-3  but  not  the  cleaved  fragment.  However,
McKinnon et al. [24] used antibodies from Idun Inc. and
Figures  9.  Elevation  of  IOP  increased  ubiquitination  in  retinal
extracts  and  decreased  ubiquitination  in  optic  nerve  extracts.
Ubiquitination  starts  with  monoubiquitination  at  multiple  lysine
residues  then  extending  the  ubiquitin  chains  by  the  sequential
addition of multiple ubiquitin moieties and that is why when using
the anti-ubiquitin antibodies, immunoreactive smear is detected that
reflects  the  covalent  attachment  of  multiple  ubiquitin  chains  to
individual  protein  molecule.  Western  blot  with  anti-ubiquitin
antibodies revealed a characteristic ubiquitin-positive smear in each
lane corresponding to the amount of ubiquitination on proteins, and
elevation of IOP enhanced ubiquitination in retinal extracts (A) while
decreased ubiquitination in optic nerve extracts (B). Abbreviations:
C-R is control retina, and T-R is elevated IOP retina; C-ON is control
optic nerve, and T-ON is elevated IOP optic nerve.
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1779detected procaspase-3 and cleaved caspase-3. We tested the
“marketed” anticleaved caspase-3 only from Cell Signaling,
and we were surprised that it recognized the procaspase-3 and
did not observe the 17 kDa fragment (data not shown). One
explanation for the lack of detection of the cleaved caspase-3
fragment is its subsequent ubiquitination and degradation.
Three studies have shown that the 17 KDa fragment is quickly
ubiquitinated and degraded by the proteasome, which may
explain its absence [70,72,73].
Also,  similar  to  earlier  reports  [74–76]  showing  a
reduction in thy-1 levels, elevation of IOP and intravitreal
ET-1 injection resulted in decreased thy-1 levels (Figures
6A,B). Both Huang et al. and Schlamp et al. [74,75] reported
a  reduction  in  thy-1  levels  very  early  following  IOP  that
preceded the actual reduction of RGC number. Therefore, a
reduction in thy-1 occurs in advance of detectable ganglion
cell loss and both studies have suggested that thy-1 serves as
an early marker of RGC stress but not a marker of RGC loss.
In summary, the current study reports a novel finding of
increased expression of AQP4 in ON astrocytes that may be
linked to cell hypertrophy. However, it remains to be verified
that  AQP4  inhibition  or  knockout  may  prevent  or  delay
hypertrophy. This suggests that the levels of AQP4 in human
glaucomatous  eyes  need  further  study.  Increases  in  IOP
Figure  10.  Elevation  of  intraocular  pressure  decreased  UCH-L1
mRNA levels. Total RNA was isolated and transcribed into cDNA.
Real-time PCR was performed using specific primers (see Methods).
mRNA expression of UCH-L1 was adjusted to the mRNA copies of
β-actin (reference gene). Results indicate that mRNA expression
level of UCH-L1 was significantly lower in elevated intraocular
pressure (IOP) retinas compared to control. UCH-L1 commonly
linked to other neurodegenerative diseases, may play a role in optic
nerve degeneration. Data are expressed as a ratio of the control value
and  each  column  represents  mean±SEM.  The  asterisk  denotes
statistical significance of ratio from IOP treatment versus that of
control as determined by One-way ANOVA and Tukey multiple
comparison test at p<0.05.
appear also to affect AQP4 and ubiquitination levels distinctly
in retina and optic nerve. The decreased ubiquitination in
axons  may  increase  the  levels  of  proapoptotic  proteins
normally degraded by the proteasome and thus contributes to
axonal degeneration following elevated IOP. Finally, similar
to other neurodegenerative diseases, UCH-L1 may also be
involved in IOP-induced retinal damage.
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